Core Viewpoint - Everbright Bank's H-shares are initiated with a "Buy" rating and a target price of HKD 4.62, corresponding to a 2025E PB of 0.50 times, supported by strong group resources and a competitive edge in wealth management and financial markets [1] Group Strategy and Resource Support - The bank benefits from comprehensive financial resources from the Everbright Group, enhancing its non-interest income through a "commercial bank + investment bank + private bank" service model [1] - Everbright Bank's wealth management subsidiary leads in scale, with a total asset size of CNY 1.82 trillion as of the end of H1 2025, establishing a competitive advantage in wealth management [1] Solid Fundamentals and Risk Clearance - The bank is actively reducing high-cost deposits and has cleared existing risks, with a stable non-performing loan (NPL) ratio of 1.25% since 2024 [2] - As of August 19, the implied NPL ratio based on current PB is significantly higher than the actual NPL ratio, indicating a strong asset quality [2] Valuation and Dividend Yield - The bank's stock is seen as undervalued with a high dividend yield, with a projected dividend payout ratio of 30.14% for 2024 and a 2025E PB/dividend yield of 0.39 times/5.77% [2] - Shareholder confidence is reflected in the planned share buybacks by the Everbright Group, which aims to acquire up to 2% of the total share capital within a year [2] Market Perspective and Profit Forecast - There is a divergence between market concerns regarding asset quality and Everbright Bank's actual risk clearance achievements, with a financial investment provision coverage ratio exceeding 200% [3] - Profit forecasts for 2025-2027 indicate a growth in net profit of 0.7%/2.4%/3.9%, with corresponding BVPS of CNY 8.47/8.77/9.32, leading to a target PB of 0.50 times for 2025 [3]

Group 1 - The Hang Seng Index rose by 0.62% to 25,426.53 points, with the Hang Seng Tech Index increasing by 1.96% and the Hang Seng China Enterprises Index up by 1.01% on August 18 [1] - The market's half-day trading volume reached HKD 171.95 billion, indicating active trading conditions [1] - Notable gainers included NIO-SW, which surged by 8.04%, JD Health rising by 6.94%, and SenseTime-W increasing by 5.20%, while Hua Hong Semiconductor fell by 5.89% and Sunny Optical Technology declined by 2.39% [1] Group 2 - The valuation pressure on the Hong Kong tech sector has been fully released after nearly a quarter of adjustment, with improved risk sentiment and ample liquidity laying a solid foundation for the next phase of growth [1] - The market is awaiting a strong thematic narrative to catalyze a new wave of enthusiasm in the Hong Kong tech sector [1] - The structural changes in the Hong Kong market have led to technology and consumer sectors now accounting for a significant portion of the market, shifting away from the previous dominance of finance and real estate [1] Group 3 - Global capital reallocation is expected to make Chinese assets a safe haven as overseas funds seek alternatives to dollar-denominated assets [2] - The Hong Kong market is experiencing a qualitative change with an influx of high-quality companies, which is fundamental for the sustainable bullish trend in the market [2] - The proportion of overseas funds allocated to Chinese assets remains relatively low, suggesting potential for future inflows if market sentiment stabilizes and international relations improve [2] Group 4 - The valuation system is undergoing a significant upgrade, with the Hang Seng Index's PE ratio rising from approximately 7.5 times to 11.6 times, aligning with the ten-year average and indicating room for further appreciation [2] - The Hong Kong tech sector is entering a golden window for systematic valuation reshaping, driven by multiple favorable factors including AI demand and rational market behavior [2] - The launch of the Hong Kong Stock Connect Tech ETF (159101) provides investors with an excellent opportunity to invest in leading tech companies in Hong Kong [2]

Core Viewpoint - The recent listings of leading A-share companies, Ningde Times and Heng Rui Pharmaceutical, on the Hong Kong stock market at a premium to their A-share prices have sparked interest in the "revaluation of Hong Kong assets" [1][12]. Market Performance - The Hong Kong stock market has experienced a valuation recovery, with the Hang Seng Index, Hang Seng China Enterprises Index, and Hang Seng Technology Index rising by 16.06%, 15.74%, and 15.43% respectively since the beginning of the year, outperforming US and Asia-Pacific markets [1][3]. - As of May 26, 2025, southbound funds have seen a cumulative net inflow exceeding 620 billion yuan [5]. Investment Trends - The inflow of southbound funds has shifted from high-dividend sectors like banks to technology, healthcare, and consumer sectors, indicating a structural change in the Hong Kong market [4][7]. - The concentration of market capitalization in financial, technology, and consumer sectors aligns with the current macroeconomic environment, appealing to investors seeking "certainty + flexibility" in asset allocation [4][9]. Future Outlook - Analysts predict that the Hong Kong market may attract more domestic and foreign incremental capital due to structural changes and the recognition of high-quality Chinese assets [8][10]. - The valuation of the Hang Seng Index has improved from around 7.5 times to 10.5 times price-to-earnings ratio, suggesting further room for growth compared to historical highs [11]. Sector Preferences - Investment institutions are favoring sectors such as technology, innovative pharmaceuticals, and new consumption in the Hong Kong market [13]. - The innovative pharmaceutical sector is expected to experience significant growth, with 2025 being a pivotal year for revenue and profitability [14]. Conclusion - The Hong Kong stock market is undergoing a transformation, with a focus on high-quality assets and a shift in investor sentiment, which may lead to sustained performance and further investment opportunities [10][12].